Back to today’s briefing

Story perspectives

Duchenne Muscular Dystrophy Market to Double by 2033

2/14/2025

24 2

Summary

Story summary

The Duchenne muscular dystrophy (DMD) market is set to soar from $2.3 billion in 2023 to an impressive $5.2 billion by 2033, fueled by innovative treatments like Sarepta's Elevidys. Exon-skipping therapies are at the forefront of this growth, yet a pressing need for solutions for non-ambulatory patients lingers, highlighting the urgency for continued advancements.

1 of 1

Story summary

The Duchenne muscular dystrophy (DMD) market is set to soar from $2.3 billion in 2023 to an impressive $5.2 billion by 2033, fueled by innovative treatments like Sarepta's Elevidys. Exon-skipping therapies are at the forefront of this growth, yet a pressing need for solutions for non-ambulatory patients lingers, highlighting the urgency for continued advancements.